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Background: The significance of upfront systemic therapies as an alternative to whole brain radiotherapy 
(WBRT) for multiple brain metastases (BM) is debatable. Our purpose is to investigate if peritumoral edema 
could predict the intracranial response to systemic chemotherapy (chemo) in patients with advanced non-
squamous non-small cell lung cancer (non-SQ-NSCLC) and synchronous multiple BM. 
Methods: In this observational cohort study, we evaluated the outcome of 28 patients with multiple BM 
(≥3) treated with chemo based on cisplatin/carboplatin plus pemetrexed (chemo, group A, n=17) or WBRT 
plus subsequent chemo (group B, n=11). The intracranial response, assessed by the response assessment 
neuro-oncology (RANO) BM criteria, was correlated with the degree of BM-associated edema estimated by 
the maximum diameter ratio among fluid attenuated inversion recovery (FLAIR) and gadolinium-enhanced 
T1WI (T1Gd) per each BM at the baseline brain magnetic resonance imaging (MRI).
Results: No differences were observed in baseline characteristics between both groups, except for the 
number of patients under steroid treatment that was clearly superior in group B (P=0.007). Median OS 
was similar between groups. Regarding FLAIR/T1Gd ratio (F/Gd), patients treated with chemo alone 
exhibited significantly higher values (P=0.001) in those who developed intracranial progression disease (PD)  
(2.80±0.32 mm), compared with those who achieved partial response (PR) (1.30±0.11 mm) or stable disease 
(SD) (1.35±0.09 mm). In patients treated with WBRT, F/Gd ratio was not predictive of response. 
Conclusions: Peritumoral edema estimated by F/Gd ratio appears a promising predictive tool to identify 
oligosymptomatic patients with multiple BM in whom WBRT can be postponed. 
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Introduction
Brain metastases (BM) are the most frequent type of brain 
tumor in adults, accounting for 10–30% of all adult solid 
tumors (1-3). Approximately 50% of all BM account for 
lung cancer (4). Regarding non-small cell lung cancer 
(NSCLC), the incidence of BM represents 10–20% 
among newly diagnosed patients and reaches 30–40% 
in subsequent diagnoses after the primary tumor (5,6). 
BM survival prognosis differs among tumor histology 
subtypes, representing less than 2 years in cases of non-
oncogene addicted NSCLC. Fortunately, this dismal 
prognosis is changing as a result of an early BM diagnosis in 
asymptomatic or oligosymptomatic stages (7).
Historically, patients with multiple BM have been 
excluded from most clinical trials and their therapeutic 
approaches have usually been palliative; with whole brain 
radiation therapy (WBRT) being the standard of care (8). 
Nevertheless, the evidence on the efficacy and benefit of 
WBRT is poor. The first conducted studies were series of 
cases from the 50s and 60s (9). From this date onwards, 
only two randomized, phase 3 clinical trials have addressed 
this question; one conducted in the pre-computed 
tomography scan era (10), and the most recent, despite 
improving local control, without showing any significant 
impact on patients’ quality of life and survival rates (11). 
In addition, as most BM patients were supposed to have 
a poor prognosis, WBRT toxicity studies, such as neuro-
cognitive dysfunction, have been limited (12). However, 
the improvement in overall survival (OS) combined 
with recent results on early cognitive impairment have 
increased the relevance of neurocognition monitoring and 
maintenance (13). In this setting, systemic therapies, such 
as conventional chemotherapy (chemo) or less controversial 
immunotherapies with immune checkpoint inhibitors 
(ICIs) (14), have become an alternative approach to WBRT 
in patients with multiple BM. 
In the era of pre-molecular testing, clinical trials using 
chemo had already been conducted, including patients 
with multiple asymptomatic to oligosymptomatic BM from 
NSCLC (single arm-phase II and randomized phase III 
studies). The findings of these studies revealed a clinically 
meaningful intracranial activity with brain response rates 
of 30–40% in platinum-pemetrexed based chemo regimens 
(15-17). In addition, development of new targeted therapies 
for oncogene-addicted NSCLC has also contributed to 
increase the intracranial response rates (18-20). Similar 
effects have been reported by using systemic therapies with 
other tumor types, as HER2-positive breast cancer (21) and 
BRAFV600E-mutated melanoma patients (22-24). On the 
other hand, immunotherapy can be an alternative frontline 
treatment for patients without driver oncogenes as long 
as the tumour expresses PD-L1 equal or superior to 50% 
(25-27). Additionally, immunotherapy in combination with 
chemo has also been approved as a frontline treatment 
regardless of PD-L1 expression (14,28,29). Unfortunately, 
apart from a two-phase II trials (30,31) and a pooled analysis 
of KEYNOTE-189 (32) none of the studies have been 
specifically designed to evaluate the intracranial response in 
patients with advanced NSCLC and multiple BM.
From a biological perspective, the blood-brain barrier 
(BBB) is structurally disrupted and functionally impaired 
with metastatic tumor growth, among others, by matrix 
tumor cells metalloproteinases (5). However, the potential 
increase in the permeability may be counterbalanced by 
the edema of surrounding tumor cells. The interstitial 
fluid pressure generated by this peritumoral edema might 
hinders the adequate drug diffusion to central nervous 
system (CNS). Towards this view, the interplay between 
these two major forces would be a determinant on the final 
intracranial response.
The aim of this current exploratory study was to 
investigate if peritumoral edema could have a predictive 
role on intracranial response to systemic chemo in patients 
with newly diagnosed non-squamous non-small cell lung 
cancer (non-SQ-NSCLC) and synchronous multiple BM. 
We present the following article in accordance with the 




The study was conducted in accordance with the 
Declaration of Helsinki (as revised in 2013). The study was 
approved by institutional research committee (PR005/20) 
and individual consent for this retrospective analysis was 
waived.
Patients were recruited retrospectively from the Thoracic 
Oncology Unit, Catalan Institute of Oncology, L'Hospitalet 
de Llobregat between 2013 and 2016. Demographic and 
clinical characteristics, baseline and longitudinal (every 
3 months) MRI images were collected together with 
OS data. All patients, comprising our study sample were 
followed for at least 1 year. 
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Participants
Eligible for inclusion were adult patients with newly 
diagnosed non-squamous NSCLC and synchronous 
multiple BM, defined as ≥3 BM in a period not exceeding 
30 days from diagnosis of the primary tumor. We have 
excluded patients having received any previous systemic or 
local brain treatment [neurosurgical resection, stereotactic 
radiosurgery (SRS) or WBRT], those lacking baseline brain 
MRI availability, exclusively non measurable cerebral disease 
and those carrying activating mutations of the epidermal 
growth factor receptor (EGFR) or anaplastic lymphoma 
kinase (ALK) re-arrangements.
Treatment regimen
Patients were treated according to the plan defined by the 
multidisciplinary tumor board, and were classified for the 
analysis according to the therapeutic approach: upfront 
chemo alone (group A, n=17) or WBRT plus subsequent 
chemo (group B, n=11). Group A patients received either 
intravenous cisplatin 75 mg/m2 or carboplatin [area under 
the curve (AUC) 5] plus pemetrexed 500 mg/m2 every 
3 weeks up to 4–6 cycles followed by maintenance 
pemetrexed until disease progression or unacceptable 
toxicity. Group B patients received WBRT with a dose of 
30 Gy in 10 fractions daily, followed by systemic chemo as 
in group A. 
Enrolled patients without any neurological deficit 
received upfront chemo. Whereas patients with the 
presence of neurologic symptoms received WBRT followed 
by chemo. Patients with medically, well-controlled, seizures 
or headache, those with mild paresis of extremities, defined 
with an Medical Research Council (MRC) score of 4, or 
pure sensory symptoms without functional impairment were 
considered as patients without neurological symptoms and 
were thus allocated in group A to receive monotherapy with 
upfront systemic chemo. 
MRI data
Brain MRI scans were performed using 1 of 3 MRI systems 
(Philips Ingenia S 3T with 32-channel head coil, Philips 
Medical System, Best, The Netherlands). The images 
obtained and analyzed on 1.5T systems were acquired with 
axial 5-mm slices with 0.5-mm gap for both gadolinium-
enhanced T1-weighted image (T1Gd) and fluid attenuated 
inversion recovery (FLAIR) sequences, whilst those from 
3T system were axial 3-mm reconstructions of a 3D sagittal 
acquisition of 0.8 mm and no gap. 
The extension of edema was estimated by calculating the 
ratio between the maximum diameter in FLAIR and T1Gd 
sequences (F/Gd) in the axial plane per each BM depicted 
at the baseline MRI (see Figure 1). Enrolled patients had an 
available baseline brain MRI with measurable brain disease 
according to the response assessment neuro-oncology 
(RANO) BM criteria, which was used to classify the 
response to the treatment as progressive disease (PD), stable 
disease (SD) and partial response (PR) (33). 
Statistical analysis
Descriptive data was presented as mean and standard 
deviation or median and range for continuous variables, 
and as observed counts and percentages for categorical 
variables. Intergroup comparisons were performed using 
Chi-square, Student’s t-text and ANOVA depending on 
the variable’s nature. In the cases where the variable did 
not follow a normal distribution, a Mann Whitney U test 
was applied. Post-hoc Tukey test was applied when multiple 
intragroup comparisons were performed. Survival curves 
were obtained using Kaplan-Meier method and compared 
by log rank test. Finally, receiver operating characteristic 
(ROC) analysis was applied to identify the most appropriate 
cut-off for the F/Gd ratio to predict the BM response. All 
tests were two-tailed and P values <0.05 were considered 
significant. Patients missing main variable (baseline MRI) 
were excluded from the analysis. Statistics analyses were 
performed using IBM SPSS Statistics Software (Version 
25.0; IBM Corp, Armonk, NY, USA). 
Results 
Characteristics of the participants
A total of 54 patients diagnosed with NSCLC BM from 
2014 to 2016 were identified, from which 28 (52%) meet the 
selection criteria. A total of 26 patients from the core study 
sample were eventually excluded for the following reasons: 
previous local or systemic treatment (n=7), non-available 
baseline MRI (n=2), exclusively non measurable cerebral 
disease (n=4) and carrying EGFR or ALK mutations 
(n=13). Demographic, clinical, tumor-related data, and OS 
of the 28 patients finally included are described in Table 
1. There were no significant differences between groups 
for almost all variables. However, the number of patients 
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under steroid treatment was clearly superior in the WBRT 
plus chemo group (P=0.007). Median progression-free 
survival (PFS) and OS were comparable between group A 
and B (10.6 vs. 8.6 months, P=0.449 for PFS; and 12.9 vs. 
10.9 months, P=0.317 for OS, respectively). Among patients 
allocated in group A, 41% [7/17] were rescued with WBRT 
at intracranial progression during their follow-up. Only 
3 (11%) out of 28 evaluable patients were still alive at the 
moment of data collection.
Neuroimaging findings
According to the first intracranial response evaluation 
(3 months after initial treatment), results were distributed as 
follows: PR 29% (n=5), SD 53% (n=9) and PD 18% (n=3) 
of patients in group A; and PR 55% (n=6), SD 27% (n=3) 
and PD 18% (n=2) of patients in group B. Patients treated 
with WBRT plus chemo had significantly higher values of 
F/Gd ratio, compared to those treated with upfront chemo 
alone (2.26±0.99 vs. 1.57±0.62 mm, respectively; P=0.008).
F/Gd ratio in group A was higher in those who 
developed intracranial PD (2.80±0.32 mm), compared 
to those who achieved either PR (1.30±0.11 mm) or SD 
(1.35±0.09 mm). ANOVA test showed a significant effect on 
F/Gd ratio between response subgroups at the P<0.05 level 
[F(2,46) =7.749; P=0.001]. Post-hoc comparisons indicated 
that the F/Gd ratio was significantly higher in PD subgroup 
compared to both SD and PR subgroups (P=0.002 and 
P=0.001, respectively). 
Conversely, the corresponding F/Gd ratio of group B 
did not show significant differences according to the BM 
response status: PD (2.25±0.30), PR (2.50±0.21) and SD 
(1.40±0.37) [F(2,31) =0.061; P=0.941]. 
Additionally, in order to identify the most discriminating 
Figure 1 Evaluation of intracranial response before starting chemo treatment (A, FLAIR; B, T1Gd) and after 8 weeks under chemo 
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cut-off value for F/Gd ratio, a ROC analysis was performed 
in group A, showing a 2.1 cut-off value on the F/Gd ratio, 
with a sensitivity of 80% and a specificity of 83.8% [AUC 
0.851, 95% confidence interval (CI): 0.689–1.014], P=0.005, 
for benefit as a result of upfront systemic treatment 
(Figure 2). 
Discussion 
Despite the tellingly poor prognosis of cancer patients 
with multiple BM (≥3), the growing evidence of clinically 
meaningful intracranial activity of systemic therapies is 
leading towards a paradigm shift on the optimal sequencing 
of BM treatment; especially for those patients who are in 
an oligo or asymptomatic stage and for whom long term-
survivals are expected. 
Current knowledge, suggesting that the normal 
functioning of BBB in BM is disrupted, has opened new 
avenues to investigate the role of systemic chemo alone or 
in combination with immunotherapy as an effective and safe 
frontline treatment (14,25-32). However, the complexity of the 
Figure 2 ROC curve plot to predict the BM response in patients 
treated with chemo alone according to F/G ratio. ROC, receiver 
operating characteristic; BM, brain metastases; F/Gd, FLAIR/
T1Gd ratio; FLAIR, fluid attenuated inversion recovery; T1Gd, 
gadolinium-enhanced T1-weighted image.




Group A (chemo) 
(N=17)
Group B (WBRT + chemo) 
(N=11)
P value
Gender, n (%) 0.903
Male 20 [71] 12 [71] 8 [73]
Female 8 [29] 5 [29] 3 [27]
Age, years at diagnosis (mean ± SD) 55.57±8.68 55.79±8.55 55.24±9.30 0.865
Smokers, n [%] 26 [93] 15 [89] 11 [100] 0.238
Smoking, pack-year (mean ± SD) 35.31±8.94 32.17±27.74 40.00±15.09 0.418
Brain metastases at diagnosis (n), median [range] 4 [3–5] 4 [3–5] 3 [3–5] 0.697
Patients with extracranial metastases at diagnosis, n [%] 20 [71] 11 [61] 9 [80] 0.336
Number of extracranial organs affected, median, [range] 2 [0–4] 2 [0–4] 1 [0–4] 0.147
Steroids treatment, n [%] 0.007
Yes 20 [71] 9 [53] 11 [100]
No 8 [29] 8 [47] 0
DS-GPA 1–4, median [range] 2 [1–4] 2 [1–4] 2 [1–3.5] 0.394
KPS 0–100, median [range] 90 [70–100]  80 [70–100] 90 [70–100] 0.201
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microenvironment surrounding the tumor cell and tumor cell 
barrier itself, hinders the chances of an adequate intracranial 
response. The biomechanical and biochemical signals that 
exist around the deliberation systems of drugs to the brain is 
arousing great interest among the scientific community. We 
have focused on conventional chemo since our explored cohort 
of patients were treated with this therapy. However, this issue 
can also be extrapolated to other types of systemic treatments. 
To our knowledge this is the first exploratory study 
that evaluates the extent of peritumoral edema as a potent 
determinant in predicting resistance to systemic therapy.
To test the hypothesis, we characterized the extension of 
edema estimated by routine MRI sequences (F/Gd ratio), 
as a supporting clinical tool to predict the intracranial 
response in NSCLC patients and synchronous multiple 
oligosymptomatic BM. Our results showed that cut-off 
values of F/Gd ratio over 2.1 are associated with chemo 
failure in those oligosymptomatic BM patients, who were 
treated with chemo alone (group A). 
On the contrary, F/Gd ratio failed to be predictive 
in WBRT plus chemo (group B)-treated patients with 
symptomatic BM. This effect might be partly explained by 
the higher proportion of patients in group B treated with 
corticosteroids. As it is well known, corticosteroids have an 
anti-inflammatory effect that can contribute to a reduction 
in the vascular permeability; thus, stabilizing the BBB and 
consequently making access from chemo to CNS even 
more challenging. Furthermore, an alternative explanation 
might have to do with the cytotoxic effect of radiotherapy 
on the irradiated cells, which it is not dependent on the 
permeability of the vessels and can also contribute to an 
increase of the edema extension. 
Other small retrospective studies focused on radiosurgery 
treatment (SRS) alone in brain oligo-metastases from 
NSCLC have also shown the extent of perilesional edema as 
a predictive factor of response and brain progression (34,35). 
In relation to chemo, there is a lack of current studies on 
radiological predictive markers of intracranial response. 
However, they have been explored in other systemic 
therapies. Recently, a retrospective study including patients 
with de novo BM of EGFR-mutated NSCLC has reported 
that MRI characteristics, including tumor necrosis, rim 
enhancement and specific tumor locations, seem to predict 
treatment response (36). In addition, another recently 
retrospective study based on melanoma BM patients 
treated with ICIs, has described MRI radiomic features as a 
potential biomarker to predict intratumoral heterogeneity 
and risk of intracranial progression (37).
In order to minimize the heterogeneity of the baseline 
demographic and clinical characteristics of our study 
population, we intentionally included patients with the same 
tumor histology, staging of extra and intracranial disease and 
treatment naïve. Nonetheless, we have to acknowledge that the 
study has several limitations. It is an exploratory retrospective 
study without pre-planned sample size calculation, with the 
consequent risk of selection and measurement bias. Moreover, 
we had to apply strict inclusion criteria to obtain a homogenous 
cohort, decreasing our final sample size. Thus, the unknown 
power of this sample precludes extract firm conclusions about 
survival benefits between the two analyzed groups. Finally, the 
measurement of lesions diameter was also a potential source of 
bias. In order to reduce it, measurements were performed by 
two independent properly trained neuroradiologists following 
RANO BM criteria. 
Conclusions
To summarize, the extension of perilesional edema 
measured by F/Gd ratio seems a promising tool to identify 
oligosymptomatic patients with multiple BM in whom 
upfront monotherapy with chemo should be considered. 
Therefore, those oligosymptomatic patients might benefit 
from upfront chemo which will allow WBRT to be 
postponed, avoiding its detrimental effects on neurocognition 
and quality of life. Nonetheless, we must handle these 
preliminary results with caution as prospective and larger 
sample studies are needed to validate the findings.
Acknowledgments
Funding: This work was partially supported by a grant from 
Instituto de Salud Carlos III (ISCIII) (PI18/01253 to MS) 
and European Regional Development Fund (ERDF). We 
also thank CERCA programme/Generalitat de Catalunya 
for Institutional support.
Footnote
Reporting Checklist: The authors have completed the 
STROBE reporting checklist. Available at http://dx.doi.
org/10.21037/atm-20-6497
Data Sharing Statement: Available at http://dx.doi.
org/10.21037/atm-20-6497
Annals of Translational Medicine, Vol 9, No 8 April 2021 Page 7 of 8
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2021;9(8):648 | http://dx.doi.org/10.21037/atm-20-6497
Conflicts of Interest: All authors have completed the ICMJE 
uniform disclosure form (available at http://dx.doi.
org/10.21037/atm-20-6497). Dr. MD reports personal fees 
from BMS, personal fees from Roche, personal fees from 
Astrazeneca, outside the submitted work. Dr. NV reports 
personal fees from Boehringer Ingelheim, personal fees 
from Roche, personal fees from Lilly, outside the submitted 
work. Dr. RP reports personal fees from Boehringer 
Ingelheim, personal fees from Roche, personal fees from 
Lilly, personal fees from AstraZeneca, personal fees from 
BMS, personal fees from MSD, outside the submitted 
work. Dr. EN reports grants and personal fees from Roche, 
grants and personal fees from Pfizer, personal fees from 
Lilly, personal fees from Bristol-Myers Squibb, grants and 
personal fees from Merck Serono, personal fees from Merck 
Sharp & Dohme, personal fees from AstraZeneca, personal 
fees from Amgen, personal fees from Takeda, personal fees 
from Boehringer Ingelheim, outside the submitted work. 
The other authors have no conflicts of interest to declare.
Ethical Statement: The authors are accountable for all 
aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved. The study was 
conducted in accordance with the Declaration of Helsinki (as 
revised in 2013). The study was approved by institutional 
research committee (PR005/20) and individual consent for 
this retrospective analysis was waived.
Open Access Statement: This is an Open Access article 
distributed in accordance with the Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 International 
License (CC BY-NC-ND 4.0), which permits the non-
commercial replication and distribution of the article with 
the strict proviso that no changes or edits are made and the 
original work is properly cited (including links to both the 
formal publication through the relevant DOI and the license). 
See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
1. Gavrilovic IT, Posner JB. Brain metastases: epidemiology 
and pathophysiology. J Neurooncol 2005;75:5-14.
2. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence 
proportions of brain metastases in patients diagnosed (1973 
to 2001) in the Metropolitan Detroit Cancer Surveillance 
System. J Clin Oncol 2004;22:2865-72.
3. Berghoff AS, Schur S, Füreder LM, et al. Descriptive 
statistical analysis of a real-life cohort of 2419 patients 
with brain metastases of solid cancers. ESMO Open 
2016;1:e000024.
4. Chamberlain MC, Baik CS, Gadi VK, et al. Systemic 
therapy of brain metastases: non-small cell lung cancer, 
breast cancer, and melanoma. Neuro Oncol 2017;19:i1-24.
5. Preusser M, Winkler F, Valiente M, et al. Recent advances 
in the biology and treatment of brain metastases of non-
small cell lung cancer: summary of a multidisciplinary 
roundtable discussion. ESMO Open 2018;3:e000262. 
6. Edelman MJ, Belani CP, Socinski MA, et al. Outcomes 
associated with brain metastases in a three-arm phase III 
trial of gemcitabine containing regimens versus paclitaxel 
plus carboplatin for advanced non-small cell lung cancer. J 
Thorac Oncol 2010;5:110-6.
7. Planchard D, Popat S, Kerr K, et al. Metastatic Non-
Small-Cell Lung Cancer: ESMO Clinical Practice 
Guidelines for diagnosis, treatment and follow-up. Ann 
Oncol 2018;29:iv192-237. 
8. Reck M, Popat S, Reinmuth N, et al. ESMO Guidelines 
Working Group. Metastatic non-small-cell lung cancer 
(NSCLC): ESMO Clinical Practice Guidelines for diagnosis, 
treatment and follow-up. Ann Oncol 2014;25:iii27-39.
9. Chao JH, Phillips R, Nickson JJ. Roentgen-ray therapy of 
cerebral metastases. Cancer 1954;7:682-9.
10. Horton J, Baxter DH, Olson KB. The management of 
metastases to the brain by irradiation and corticosteroids. 
Am J Roentgenol Radium Ther Nucl Med 1971;111:334-6.
11. Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone 
and supportive care with or without whole brain 
radiotherapy in treating patients with non-small cell lung 
cancer with brain metastases unsuitable for resection or 
stereotactic radiotherapy (QUARTZ): results from a phase 3, 
non-inferiority, randomised trial. Lancet 2016;388:2004-14.
12. Brown PD, Ahluwalia MS, Khan OH, et al. Whole-
Brain Radiotherapy for Brain Metastases: Evolution or 
Revolution? J Clin Oncol 2018;36:483-91.
13. Brown, PD, Jaeckle K, Ballman KV, et al. Effect of 
Radiosurgery Alone vs Radiosurgery with Whole Brain 
Radiation Therapy on Cognitive Function in Patients 
With 1 to 3 Brain Metastases: A Randomized Clinical 
Trial. JAMA 2016;316:401-9.
14. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. 
Pembrolizumab plus Chemotherapy in Metastatic Non-
Small-Cell Lung Cancer. N Engl J Med 2018;378:2078-92.
15. Alsidawi S, Chaudhary R, Karim NA. Frontline Systemic 
Therapy with Pemetrexed-Platinum in Nonsquamous 
Non-Small-Cell Lung Cancer With Asymptomatic Brain 
Alemany et al. BM edema as response factor to chemotherapy 
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2021;9(8):648 | http://dx.doi.org/10.21037/atm-20-6497
Page 8 of 8
Metastases. Am J Ther 2017;24:e111-20.
16. Barlesi F, Gervais R, Lena H, et al. Pemetrexed and 
cisplatin as first-line chemotherapy for advanced non-
small-cell lung cancer (NSCLC) with asymptomatic 
inoperable brain metastases: a multicenter phase II trial 
(GFPC 07-01). Ann Oncol 2011;22:2466-70.
17. Robinet G, Thomas P, Breton JL, et al. Results of a phase 
III study of early versus delayed whole brain radiotherapy 
with concurrent cisplatin and vinorelbine combination in 
inoperable brain metastasis of non-small-cell lung cancer: 
Groupe Francais de Pneumo Cancerologie (GFPC) 
Protocol 95-1. Ann Oncol 2001;12:59-67.
18. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in 
untreated EGFR-mutated advanced non-small-cell lung 
cancer. N Engl J Med 2018;378:113-25.
19. Gadgeel S, Peters S, Mok T, et al. Alectinib vs crizotinib 
in treatment-naïve anaplastic lymphoma kinase-positive 
(ALK+) non-small-cell lung cancer: CNS efficacy results 
from the ALEX study. Ann Oncol 2018;29:2214-22.
20. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus 
crizotinib in untreated ALK positive non-small-cell lung 
cancer. N Engl J Med 2017;377:829-38.
21. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus 
capecitabine in patients with previously untreated brain 
metastases from HER2-positive metastatic breast cancer 
(LANDSCAPE): a single-group phase 2 study. Lancet 
Oncol 2013;14:64-71.
22. McArthur GA, Maio M, Arance A, et al. Vemurafenib in 
metastatic melanoma patients with brain metastases: an 
open-label, single-arm, phase 2, multicentre study. Ann 
Oncol 2017;28:634-41.
23. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients 
with Val600Glu or Val600Lys BRAF-mutant melanoma 
metastatic to the brain (BREAK-MB): a multicentre, open-
label, phase 2 trial. Lancet Oncol 2012;13:1087-95.
24. Davies MA, Saiag P, Robert C, et al. Dabrafenib plus 
trametinib in patients with BRAF(V600) mutant melanoma 
brain metastases (COMBI-MB): a multicentre, multicohort, 
open-label, phase 2 trial. Lancet Oncol 2017;18:863-73.
25. Genentech Inc., Tecentriq (atezolizumab) prescribing 
information (US FDA). Available online: https://www.
gene.com/download/pdf/tecentriq_prescribing.pdf 
26. Merck & Co. Inc., Keytruda (pembrolizumab) prescribing 
information (US FDA). Available online: https://www.merck.
com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
27. Reck M, Rodríguez-Abreu D, Robinson AG, et al. 
Pembrolizumab versus Chemotherapy for PD-L1-
Positive Non-Small-Cell Lung Cancer. N Engl J Med 
2016;375:1823-33.
28. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab 
plus Chemotherapy for Squamous Non-Small-Cell Lung 
cancer. N Engl J Med 2018;379:2040-51. 
29. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab 
for First-Line Treatment of Metastatic Nonsquamous 
NSCLC. N Engl J Med 2018;378:2288-301. 
30. Goldberg SB, Gettinger SN, Mahajan A, et al. 
Pembrolizumab for patients with melanoma or non-small-
cell lung cancer and untreated brain metastases: early 
analysis of a non-randomised, open-label, phase 2 trial. 
Lancet Oncol 2016;17:976-83.
31. Besse B, Le Moulec S, Mazières J. et al. Bevacizumab in 
Patients with Nonsquamous Non-Small Cell Lung Cancer 
and Asymptomatic, Untreated Brain Metastases (BRAIN): 
A Nonrandomized, Phase II Study. Clin Cancer Res 
2015;21:1896-903.
32. Powell SF, Rodríguez-Abreu D, Langer CJ, et al. 
Pembrolizumab (pembro) plus platinum-based chemotherapy 
(chemo) in NSCLC with brain metastases: Pooled analysis of 
KEYNOTE-021, 189, and 407. Ann Oncol 2019;30:v606-7.
33. Lin NU, Lee EQ, Aoyama H, et al. Response assessment 
criteria for brain metastases: proposal from the RANO 
group. Lancet Oncol 2015;16:e270-8.
34. Tini P, Nardone V, Pastina P, et al. Perilesional edema in 
brain metastasis from non-small cell lung cancer (NSCLC) 
as predictor of response to radiosurgery (SRS). Neurol Sci 
2017;38:975-82.
35. Nardone V, Nanni S, Pastina P, et al. Role of perilesional 
edema and tumor volume in the prognosis of non-small 
cell lung cancer (NSCLC) undergoing radiosurgery (SRS) 
for brain metastases. Strahlenther Onkol 2019;195:734-44.
36. Lin CY, Chang CC, Su PL, et al. Brain MRI imaging 
characteristics predict treatment response and outcome in 
patients with de novo brain metastasis of EGFR-mutated 
NSCLC. Medicine (Baltimore) 2019;98:e16766.
37. Bhatia A, Birger M, Veeraraghavan H, et al. MRI radiomic 
features are associated with survival in melanoma brain 
metastases treated with immune checkpoint inhibitors. 
Neuro Oncol 2019;21:1578-86.
Cite this article as: Alemany M, Domènech M, Argyriou AA, 
Vilariño N, Majós C, Naval-Baudin P, Lucas A, Palmero R, 
Simó M, Nadal E, Bruna J. Perilesional edema in brain 
metastases as predictive factor of response to systemic therapy 
in non-small cell lung cancer patients: a preliminary study. Ann 
Transl Med 2021;9(8):648. doi: 10.21037/atm-20-6497
